[CAS NO. 1241280-25-0] SAE-14
PRODUCTS SPECIFICATIONS [1241280-25-0]
DESCRIPTION [1241280-25-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 364.36 |
| Molecular Formula | C19H19F3N2O2 |
| SMILES | O=C(NC1=CC(N2CCOCC2)=CC(F)=C1)CCC3=CC=C(F)C(F)=C3 |
Summary
SAE-14 (compound SAE-14) is a potent, specific GPR183 antagonist with an IC 50 value of 28.5 nM, can antagonize 7α, 25-OHC–induced calcium mobilization with IC 50 value below 50 nM in HL-60 cells. GPR183 antagonist-1 can reverse allodynia in mice [1] .
IC50 & Target
IC50: 28.5 nM (GPR183) [1]
In Vitro
SAE-14 (compound SAE-14) can able to antagonize 7α, 25-OHC–induced calcium mobilization with an IC 50 value below 50 nM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | The human leukemia (HL)-60 cells |
| Concentration: | 5×of the antagonist |
| Incubation Time: | 15 min |
| Result: | Had GPR183-specific (IC 50 : 28.5nM) and abolished 7a, 25-OHC–induced calcium mobilization in the HL-60 cells. |
In Vivo
SAE-14 (compound SAE-14) (i.th.; 2.9 µM; once) can reverse nerve injury-induced allodynia in mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male and female ICR mice [1] |
| Dosage: | 2.9 µM |
| Administration: | intrathecal (i.th.) injections; 2.9 µM; once |
| Result: | Reversed CCI-induced mechanical allodynia in a time-dependent manner. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 274.45 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7445 mL | 13.7227 mL | 27.4454 mL |
| 5 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL |
| 10 mM | 0.2745 mL | 1.3723 mL | 2.7445 mL |